NovoMix 30
PreclinicalSmall molecule
NovoMix 30 is one of 3 small molecule programs targeting Latent Autoimmune Diabetes in Adults. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Latent Autoimmune Diabetes in Adults
#DrugCompanyPhaseTrials
1Calciferol
Jazz PharmaceuticalsApproved
Treatment
GSKPreclinical
NovoMix 30
GGeropharm
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Latent Autoimmune Diabetes in Adults1 trial
Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)
Unknown status·—·N/A·NCT00776607·200 enrolled
Type 2 Diabetes Mellitus1 trial
Tics1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NovoMix 30. EMBL-EBI & Wellcome Sanger Institute.
- [4]